BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Dec 05, 2011
 |  BC Week In Review  |  Company News  |  Deals

Adeona, Intrexon deal

Intrexon's Human Therapeutics Division granted Adeona exclusive, worldwide rights to develop and commercialize a DNA-based therapeutic to treat pulmonary arterial hypertension (PAH). The therapeutic uses Intrexon's UltraVector technology for assembling transgenes and its RheoSwitch Therapeutic System recombinase platform for gene therapy delivery. Adeona will use Intrexon's technologies to develop a therapeutic for continuous...

Read the full 245 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >